Ted O Akhiwu, Comfort Adewunmi, Mariah Bilalaga, Joseph O Atarere, Greeshma Gaddipati, Onyema G Chido-Amajuoyi, Diamond K Eziuche, Henry Onyeaka, Hermioni L Amonoo
{"title":"Clinical trial knowledge among cancer survivors in the United States: the role of health information technology.","authors":"Ted O Akhiwu, Comfort Adewunmi, Mariah Bilalaga, Joseph O Atarere, Greeshma Gaddipati, Onyema G Chido-Amajuoyi, Diamond K Eziuche, Henry Onyeaka, Hermioni L Amonoo","doi":"10.1007/s10552-024-01928-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Clinical trials are essential to the advancement of cancer care. However, clinical trial knowledge and participation remain critically low among adult patients with cancer. Health information technology (HIT) could play an important role in improving clinical trial knowledge and engagement among cancer survivors.</p><p><strong>Methods: </strong>We used data from 3,794 adults who completed the 2020 Health Information National Trends Survey, 626 (16.2%) of whom were cancer survivors. We examined the prevalence of HIT use in the study population and by cancer history using chi-squared tests. We used multivariable logistic regression models to examine the impact of HIT use on clinical trial knowledge for cancer survivors and respondents with no cancer history, respectively.</p><p><strong>Results: </strong>Approximately 63.8% of cancer survivors reported having some knowledge of clinical trials. Almost half of the cancer survivors used HIT to communicate with doctors (47.1%) and make health appointments (49.4%), 68.0% used HIT to look up health information online and 42.2% used it to check test results. In the adjusted models, the use of HIT in communicating with doctors [OR 2.79; 95% CI (1.41, 5.54)], looking up health information online [OR 2.84; 95% CI (1.04, 7.77)], and checking test results [OR 2.47; 95% CI (1.12, 5.43)] was associated with having some knowledge of clinical trials.</p><p><strong>Conclusion: </strong>HIT use for engaging with the healthcare team and health information gathering is associated with higher clinical trial knowledge in cancer survivors. Given the rapid increase in mobile technology access globally and the increased use of HIT, digital technology can be leveraged to improve clinical trial knowledge and engagement among cancer survivors.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Causes & Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10552-024-01928-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Clinical trials are essential to the advancement of cancer care. However, clinical trial knowledge and participation remain critically low among adult patients with cancer. Health information technology (HIT) could play an important role in improving clinical trial knowledge and engagement among cancer survivors.
Methods: We used data from 3,794 adults who completed the 2020 Health Information National Trends Survey, 626 (16.2%) of whom were cancer survivors. We examined the prevalence of HIT use in the study population and by cancer history using chi-squared tests. We used multivariable logistic regression models to examine the impact of HIT use on clinical trial knowledge for cancer survivors and respondents with no cancer history, respectively.
Results: Approximately 63.8% of cancer survivors reported having some knowledge of clinical trials. Almost half of the cancer survivors used HIT to communicate with doctors (47.1%) and make health appointments (49.4%), 68.0% used HIT to look up health information online and 42.2% used it to check test results. In the adjusted models, the use of HIT in communicating with doctors [OR 2.79; 95% CI (1.41, 5.54)], looking up health information online [OR 2.84; 95% CI (1.04, 7.77)], and checking test results [OR 2.47; 95% CI (1.12, 5.43)] was associated with having some knowledge of clinical trials.
Conclusion: HIT use for engaging with the healthcare team and health information gathering is associated with higher clinical trial knowledge in cancer survivors. Given the rapid increase in mobile technology access globally and the increased use of HIT, digital technology can be leveraged to improve clinical trial knowledge and engagement among cancer survivors.
目的:临床试验对促进癌症治疗至关重要。然而,成年癌症患者对临床试验的了解和参与程度仍然很低。健康信息技术(HIT)可在提高癌症幸存者对临床试验的了解和参与度方面发挥重要作用:我们使用了 3,794 名完成了 2020 年健康信息全国趋势调查的成年人的数据,其中 626 人(16.2%)是癌症幸存者。我们使用卡方检验法检测了研究人群中 HIT 的使用率以及癌症病史。我们使用多变量逻辑回归模型分别检验了癌症幸存者和无癌症病史受访者使用 HIT 对临床试验知识的影响:大约 63.8% 的癌症幸存者表示对临床试验有一定的了解。近一半的癌症幸存者使用 HIT 与医生沟通(47.1%)和进行健康预约(49.4%),68.0% 的癌症幸存者使用 HIT 在线查询健康信息,42.2% 的癌症幸存者使用 HIT 查看检查结果。在调整模型中,使用 HIT 与医生沟通[OR 2.79; 95% CI (1.41, 5.54)]、在线查询健康信息[OR 2.84; 95% CI (1.04, 7.77)]和检查结果[OR 2.47; 95% CI (1.12, 5.43)]与对临床试验有一定了解有关:结论:在癌症幸存者中,使用 HIT 与医疗团队接触并收集健康信息与他们对临床试验的了解程度较高有关。鉴于全球移动技术普及率的快速增长和 HIT 使用量的增加,可以利用数字技术提高癌症幸存者的临床试验知识水平和参与度。
期刊介绍:
Cancer Causes & Control is an international refereed journal that both reports and stimulates new avenues of investigation into the causes, control, and subsequent prevention of cancer. By drawing together related information published currently in a diverse range of biological and medical journals, it has a multidisciplinary and multinational approach.
The scope of the journal includes: variation in cancer distribution within and between populations; factors associated with cancer risk; preventive and therapeutic interventions on a population scale; economic, demographic, and health-policy implications of cancer; and related methodological issues.
The emphasis is on speed of publication. The journal will normally publish within 30 to 60 days of acceptance of manuscripts.
Cancer Causes & Control publishes Original Articles, Reviews, Commentaries, Opinions, Short Communications and Letters to the Editor which will have direct relevance to researchers and practitioners working in epidemiology, medical statistics, cancer biology, health education, medical economics and related fields. The journal also contains significant information for government agencies concerned with cancer research, control and policy.